NHS ENGLAND

SPECIALISED SERVICES: POLICY AND SPECIFICATION CONSULTATION MARCH 2015

NHS England is consulting on the following (5) service specifications:

Internal Medicine

- Haemodialysis providers only delivering dialysis away from base Service Specification
- Complex specialised obesity Service Specification

Mental Health

- Gender identity services Service Specification
- Tier 4 personality disorder Service Specification

Trauma

Neuropathology Service Specification

NHS England is also consulting on the following (33) clinical commissioning policies:

Internal Medicine

- Pulmonary hypertension revision of current policy for targeted therapies to add riociguat for chronic thromboembolic pulmonary hypertension patients Clinical Commissioning Policy
- Complex specialised obesity surgery Clinical Commissioning Policy

Blood and Infection

- Stribild for the treatment of HIV-1 infection in adults Clinical Commissioning Policy
- Use of cobicistat as a booster in treatment of HIV positive adults and adolescents Clinical Commissioning Policy
- The use of rituximab as a second line agent for the eradication of inhibitors in patients with acquired haemophilia Clinical Commissioning Policy
- Treatment as prevention (TasP) in HIV infected adults Clinical Commissioning Policy
- Bedaquiline and delamanid for defined patients with MDR-XDR- TB Clinical Commissioning Policy

Cancer

- PET-CT guidelines (all ages) Clinical Commissioning Policy Statement
- Proton Beam Radiotherapy (adults, teenage and young adult, paediatrics) cancer treatment Clinical Commissioning Policy
- Proton Beam Radiotherapy Adults cancer treatment Clinical Commissioning Policy
- Proton Beam Radiotherapy Paediatrics cancer treatment Clinical Commissioning Policy
- Robotic-assisted surgical procedures for prostate cancer Clinical Commissioning Policy

Mental Health

Gender identity services Clinical Commissioning Policy

Trauma

- Cervical disc replacement for cervical radiculomyelopathy Clinical Commissioning Policy
- Duopoda for parkinsons disease Clinical Commissioning Policy
- Microprocessor controlled prosthesis knees Clinical Commissioning Policy
- High definition silicone Clinical Commissioning Policy
- Provision of multi-grip upper limb prosthesis Clinical Commissioning Policy
- Hand transplantation Clinical Commissioning Policy
- Deep brain stimulation for refractory epilepsy Clinical Commissioning Policy
- Uveitis (adults) Clinical Commissioning Policy
- <u>Uveitis (paediatrics) Clinical Commissioning Policy</u>
- Intrathecal pumps for the treatment of cancer pain Clinical Commissioning Policy
- Intrathecal pumps for the treatment of non malignant pain Clinical Commissioning Policy
- Deep brain stimulation for chronic pain clinical commissioning policy
- Occipital nerve stimulator for cluster headaches and chronic migraine Clinical Commissioning Policy

Women and Children

- Rituximab for the treatment of steroid resistant nephrotic syndrome (SRNS) in paediatrics Clinical Commissioning Policy
- Rituximab for treatment of relapsing steroid sensitive nephrotic (SSNS) in paediatrics Clinical Commissioning Policy
- Genetic testing for BRCA1 and BRCA2 mutations (breast cancer) Clinical Commissioning Policy
- Sapropterin for children Clinical Commissioning Policy
- Elosulfase vimizin for mucopolysaccharidosis IVA Clinical Commissioning Policy
- Viz ataluren for ducheene muscular dystrophy Clinical Commissioning Policy
- Sacral nerve stimulation for urinary incontinence Clinical Commissioning Policy

NHS England is also consulting on the following (2) other commissioning products

Cancer

Chemotherapy Algorithms – multi myeloma

Women and Children

UK Genetic Testing Network (UKGTN) new test recommendations – (please note: The attached report recommends a new set of genetic tests for rare inherited conditions and these are listed in attachment one. Attachment two provides information about the costs and savings that each of the tests would bring).

- UKGTN CPAG Cover Paper
- UKGTN CPAG Attachment 1 Descriptions and Clinical Utility
- UKGTN CPAG Attachment 2 Evaluations costs and savings by CRG